Abstract
In this issue of Cell Stem Cell, Bershteyn etal.1 developed a human interneuron cell therapy that reduced spontaneous seizure activity in a mouse model of mesial temporal lobe epilepsy (MTLE). The data presented here support an ongoing phase 1/2 clinical trial for the treatment of pharmaco-resistant epilepsy in patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have